Forma Therapeutics Stock Drops After Disappointing EHA Presentation For Etavopivat In Sickle Cell Disease

Forma Therapeutics Holdings Inc FMTX announced new data from its ongoing Phase 1 trial of etavopivat (FT-4202) in sickle cell disease.
Data were presented at the Annual European Hematology Association (EHA) 2021 Virtual Congress.
The presentation included initial data from the open-label extension (OLE) cohort showing etavopivat improved and sustained hematologic and hemolytic parameters.
The company also presented unblinded results from the two multiple ascending dose (MAD) cohorts, which demonstrated once-daily dosing of 300 mg or 600 mg etavopivat for 14 days improved sickle red blood cell functional health measures with effects persisting in some patients even after treatment discontinuation.
Improvement in red blood cell functional health markers was observed, including data on measures of cell membrane integrity and systemic biomarkers of inflammation and coagulation.
Price Action: FMTX shares are down 18.8% at $22.77 during the market session on the last check Friday.